StockData
Lineage Cell Therapeutics, Inc. logo

Lineage Cell Therapeutics, Inc. (LCTX) stock

LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3024% above fair value
$0.82+0.02 (+2.60%)

Close on Nov 17, 2026Market cap $206.32MP/E –Yield –

Lineage Cell Therapeutics market cap

Market capitalization is the share price multiplied by the number of shares outstanding.

Lineage Cell Therapeutics's market cap was $280.73M on Nov 11, 2026, against $405.38M a year earlier. Over the last 5 years it ranged from $94.89M to $466.79M, with a median of $234.25M.

Market Cap at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$280.73M-27.0%
2025Dec 31, 2025$384.65M+305.4%
2024Dec 31, 2024$94.89M-50.3%
2023Dec 29, 2023$190.74M-4.0%
2022Dec 30, 2022$198.77M-51.8%
2021Dec 31, 2021$412.74M+56.3%
2020Dec 31, 2020$263.98M+98.0%
2019Dec 31, 2019$133.31M+15.1%
2018Dec 31, 2018$115.85M-53.5%
2017Dec 29, 2017$248.98M-32.9%
2016Dec 30, 2016$371.01M+10.3%
2015Dec 31, 2015$336.38M+32.1%
2014Dec 31, 2014$254.73M+27.2%
2013Dec 31, 2013$200.24M+29.7%
2012Dec 31, 2012$154.37M-45.7%
2011Dec 30, 2011$284.41M–

More Lineage Cell Therapeutics figures

See a number that looks wrong?